The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease
Open accessAbstract
We developed a pipeline to integrate the proteomic technologies used from the discovery to the verification stages of plasma biomarker identification and applied it to identify early biomarkers of cardiac injury from the blood of patients undergoing a therapeutic, planned myocardial infarction (PMI) for treatment of hypertrophic cardiomyopathy. Sampling of blood directly from patient hearts before, during and after controlled myocardial injury ensured enrichment for candidate biomarkers and allowed patients to serve as their own biological controls. LC-MS/MS analyses detected 121 highly differentially expressed proteins, including previously credentialed markers of cardiovascular disease and >100 novel candidate biomarkers for myocardial infarction (MI). Accurate inclusion mass screening (AIMS) qualified a subset of the candidates based on highly specific, targeted detection in peripheral plasma, including some markers unlikely to have been identified without this step. Analyses of peripheral plasma from controls and patients with PMI or spontaneous MI by quantitative multiple reaction monitoring mass spectrometry or immunoassays suggest that the candidate biomarkers may be specific to MI. This study demonstrates that modern proteomic technologies, when coherently integrated, can yield novel cardiovascular biomarkers meriting further evaluation in large, heterogeneous cohorts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
Self-citationAddona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J., Mani, D. R., Bunk, D. M., Spiegelman, C. H., Zimmerman, L. J., Ham, A.-J. L., Keshishian, H., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1546 · Cited by 1,037
Self-citationMetabolic signatures of exercise in human plasma
Lewis, G. D., Farrell, L., Wood, M. J., Martinovic, M., Arany, Z., Rowe, G. C., Souza, A., Cheng, S., McCabe, E. L., Yang, E., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001006 · Cited by 432
Self-citationShaham, O., Wei, R., Wang, T. J., Ricciardi, C., Lewis, G. D., Vasan, R. S., Carr, S. A., Thadhani, R., Gerszten, R. E., & Mootha, V. K. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.50 · Cited by 399
Self-citation
Cited by
Next-generation proteomics: towards an integrative view of proteome dynamics
Altelaar, A. F. M., Munoz, J., & Heck, A. J. R. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3356 · Cited by 782
Plasma Proteome Profiling to Assess Human Health and Disease
Geyer, P. E., Kulak, N. A., Pichler, G., Holdt, L. M., Teupser, D., & Mann, M. (2016) · Cell Systems · doi:10.1016/j.cels.2016.02.015 · Cited by 734
“Using such technology and combining it with immunodepletion of high- andmedium-abundance proteins as well as very extensive peptide fractionation methods, it has now become possible to identify more than 1,000 (Addona et al., 2011; Cao et al., 2012; Paczesny et al., 2010) or even more than 5,000 proteins (Keshishian e…”
BackgroundUsing i RT, a normalized retention time for more targeted measurement of peptides
Escher, C., Reiter, L., MacLean, B., Ossola, R., Herzog, F., Chilton, J., MacCoss, M. J., & Rinner, O. (2012) · PROTEOMICS · doi:10.1002/pmic.201100463 · Cited by 600
Carr, S. A., Abbatiello, S. E., Ackermann, B. L., Borchers, C., Domon, B., Deutsch, E. W., Grant, R. P., Hoofnagle, A. N., Hüttenhain, R., Koomen, J. M., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036095 · Cited by 561
“When all available information about the peptides targeted is appropriately used, Tier 3 measurements are robust and powerful, representing a more refined higher throughput way to do what amounts to label-free, semi-quantitative discovery but with much better repeatability for target detection and measurement (36, 37).”
Self-citationQuantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry
Gillette, M. A., & Carr, S. A. (2013) · Nature Methods · doi:10.1038/nmeth.2309 · Cited by 495
Self-citationMurphy, E., Ardehali, H., Balaban, R. S., DiLisa, F., Dorn, G. W., Kitsis, R. N., Otsu, K., Ping, P., Rizzuto, R., Sack, M. N., et al. (2016) · Circulation Research · doi:10.1161/res.0000000000000104 · Cited by 458
Schilling, B., Rardin, M. J., MacLean, B. X., Zawadzka, A. M., Frewen, B. E., Cusack, M. P., Sorensen, D. J., Bereman, M. S., Jing, E., Wu, C. C., et al. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.017707 · Cited by 449
Bulked sample analysis in genetics, genomics and crop improvement
Zou, C., Wang, P., & Xu, Y. (2016) · Plant Biotechnology Journal · doi:10.1111/pbi.12559 · Cited by 323
Abbatiello, S. E., Schilling, B., Mani, D. R., Zimmerman, L. J., Hall, S. C., MacLean, B., Albertolle, M., Allen, S., Burgess, M., Cusack, M. P., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.047050 · Cited by 215
Self-citationClinical potential of mass spectrometry-based proteogenomics
Zhang, B., Whiteaker, J. R., Hoofnagle, A. N., Baird, G. S., Rodland, K. D., & Paulovich, A. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0135-7 · Cited by 210
Applications of targeted proteomics in systems biology and translational medicine
Ebhardt, H. A., Root, A., Sander, C., & Aebersold, R. (2015) · PROTEOMICS · doi:10.1002/pmic.201500004 · Cited by 184
Kennedy, J. J., Abbatiello, S. E., Kim, K., Yan, P., Whiteaker, J. R., Lin, C., Kim, J. S., Zhang, Y., Wang, X., Ivey, R. G., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2763 · Cited by 184
Self-citationSimon, R., Girod, M., Fonbonne, C., Salvador, A., Clément, Y., Lantéri, P., Amouyel, P., Lambert, J. C., & Lemoine, J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018861 · Cited by 92
“Molecular and Cellular Proteomics, American Society for Biochemistry and Molecular Biology, 2012, 11 (11), pp.”
BackgroundMycobacterial Esx-3 Requires Multiple Components for Iron Acquisition
Siegrist, M. S., Steigedal, M., Ahmad, R., Mehra, A., Dragset, M. S., Schuster, B. M., Philips, J. A., Carr, S. A., & Rubin, E. J. (2014) · mBio · doi:10.1128/mbio.01073-14 · Cited by 87
Self-citationNew astroglial injury-defined biomarkers for neurotrauma assessment
Halford, J., Shen, S., Itamura, K., Levine, J., Chong, A. C., Czerwieniec, G., Glenn, T. C., Hovda, D. A., Vespa, P., Bullock, R., et al. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17724681 · Cited by 75
Proteomics in heart failure: top-down or bottom-up?
Gregorich, Z. R., Chang, Y.-H., & Ge, Y. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1471-9 · Cited by 69
The opportunities of mining historical and collective data in drug discovery
Wassermann, A. M., Lounkine, E., Davies, J. W., Glick, M., & Camargo, L. M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.11.004 · Cited by 34
Rezeli, M., Végvári, Á., Donnarumma, F., Gidlöf, O., Smith, J. G., Erlinge, D., & Marko-Varga, G. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.05.016 · Cited by 33
“Quantitative mass spectrometric assays, like MRM (multiple reaction monitoring), have a huge potential in both the validation of newly discovered biomarker candidates and in the measurements of knownmarkers within a multiplex assay format in the clinical routine [2–6].”
BackgroundMethod
Metadata
- Authors
- Addona, T. A., Shi, X., Keshishian, H., Mani, D. R., Burgess, M., Gillette, M. A., Clauser, K. R., Shen, D., Lewis, G. D., Farrell, L. A., Fifer, M. A., Sabatine, M. S., Gerszten, R. E., & Carr, S. A.
- Venue
- Nature Biotechnology
- Published
- 2011-06-19
- Volume
- 29
- Issue
- 7
- Pages
- 635-643
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2083684832
- Cited by
- 249
- References
- 4
- FWCI
- 15.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.